Administration of the cytoprotectant amifostine.
Clin J Oncol Nurs
; 2(3): 101-4, 1998 Jul.
Article
em En
| MEDLINE
| ID: mdl-10232150
ABSTRACT
This article provides guidelines for the use of amifostine (Ethyol, Alza Pharmaceuticals, Palo Alto, CA, and U.S. Bioscience, Inc., West Conshohocken, PA), a pancytoprotective agent approved for reducing renal toxicity associated with cisplatin administration in patients with advanced ovarian or non-small cell lung cancer. Pretreatment with amifostine reduces the incidence of serious and cumulative chemotherapy-induced toxicities, thus improving quality of life, and allows administration of optimal doses and scheduling of chemotherapy and radiation therapy, translating into improved survival. Practical guidelines for administration of amifostine are provided in an effort to ameliorate emesis, amifostine's principle side effect.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Protetores contra Radiação
/
Cisplatino
/
Carcinoma Pulmonar de Células não Pequenas
/
Amifostina
/
Nefropatias
/
Neoplasias Pulmonares
/
Antineoplásicos
Tipo de estudo:
Guideline
Limite:
Female
/
Humans
Idioma:
En
Revista:
Clin J Oncol Nurs
Assunto da revista:
ENFERMAGEM
/
NEOPLASIAS
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Estados Unidos